The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.

Inclusion Criteria:

• Patients must have a histopathologic diagnosis of epithelial ovarian cancer.
• Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam).
• Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).
• Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.
• Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.
• Patients may have had only one prior chemotherapy regimen.

Exclusion Criteria:

• Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.
• Patients who are pregnant or breast-feeding.